In 1954 was created Handok, which is appeared as Corporate Investor.
The standard case for the fund is to invest in rounds with 10 partakers. Despite the Handok, startups are often financed by Takeda Ventures, Seventure Partners, SBI Japan-Israel Innovation Fund. The meaningful sponsors for the fund in investment in the same round are Takeda Ventures, Seventure Partners, SBI Japan-Israel Innovation Fund.
Among the most successful fund investment fields, there are Health Care, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight BIOMx. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.
The fund is generally included in less than 2 deals every year. The high activity for fund was in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars.
| Fund Name | Location |
| Ai You | Beijing, Beijing, China |
| Allegheny Financial Group | Pennsylvania, Pittsburgh, United States |
| Armada Capital | Distrito Federal, Mexico, Mexico City |
| CAC | California, San Diego, United States |
| Chinalin Securities | China, Guangdong, Tianjin |
| Emerson Ventures | Canada, Ontario, Toronto |
| Essential Pharma | Japan, Tokyo |
| First Swedish National Pension Fund | Stockholm, Stockholm County, Sweden |
| FirsTrust China | China, Shanghai |
| Jilin University Alumni Fund | - |
| Leonite Capital | New York, Spring Valley, United States |
| Media Digital Ventures | Barcelona, Catalonia, Spain |
| NA | - |
| RMB Funds | Chicago, Illinois, United States |
| TechnoPlus Ventures | Israel, Tel Aviv, Tel Aviv District |
| W Health Ventures | Boston, Massachusetts, United States |
| Weizhong Xiang Jijin | China, Jiangsu, Nanjing |
| WisdomTree | New York, New York, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
WELT | $12M | 26 Jun 2024 | South Korea, Gyeonggi-do, South Korea | ||
Spark Biopharma | $2M | 25 Nov 2021 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
WELT | 23 Mar 2021 | South Korea, Gyeonggi-do, South Korea | |||
BIOMx | $32M | 20 Feb 2019 | Israel, North District, Israel |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
WELT | $12M | 26 Jun 2024 | South Korea, Gyeonggi-do, South Korea | ||
Spark Biopharma | $2M | 25 Nov 2021 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
WELT | 23 Mar 2021 | South Korea, Gyeonggi-do, South Korea | |||
BIOMx | $32M | 20 Feb 2019 | Israel, North District, Israel |
